METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy aims to boost survival in Hard-to-Treat stomach cancers
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific m…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks safety of VYLOY in everyday cancer care
Disease control Recruiting nowThis study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo offers hope for Hard-to-Treat stomach cancer
Disease control AVAILABLEThis program provides early access to zolbetuximab, a targeted drug, combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). Participants must not have had prior chemotherapy or immunotherapy…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:18 UTC